C4 Therapeutics holders back board, pay and plan
C4 Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 24, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
C4 Therapeutics, Inc. reported the results of its annual stockholder meeting held on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors to serve until the 2029 annual meeting.
Stockholders gave a non-binding, advisory approval of named executive officer compensation and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment to the 2020 Stock Option and Incentive Plan to include outstanding pre-funded warrants in the shares counted for the evergreen increase calculation.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Votes for Hirsch: 47,797,964 votes
Votes for Fawell: 47,811,414 votes
Votes for Koppikar: 46,491,892 votes
+3 more
6 metrics
Votes for Hirsch
47,797,964 votes
Election of Class III director Andrew J. Hirsch
Votes for Fawell
47,811,414 votes
Election of Class III director Stephen Fawell, Ph.D.
Votes for Koppikar
46,491,892 votes
Election of Class III director Utpal Koppikar
Say-on-pay support
54,935,574 votes for
Non-binding advisory vote on executive compensation
Auditor ratification for
76,891,210 votes for
Ratification of KPMG LLP for FY ending Dec. 31, 2026
Plan amendment for
33,713,572 votes for
Amendment to 2020 Stock Option and Incentive Plan
Key Terms
non-binding, advisory vote, independent registered public accounting firm, evergreen provision, pre-funded warrants, +1 more
5 terms
non-binding, advisory vote financial
"The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company’s named executive officers."
independent registered public accounting firm financial
"The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
evergreen provision financial
"approved an amendment to the Company’s 2020 Stock Option and Incentive Plan to amend the evergreen provision to include any outstanding pre-funded warrants"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
pre-funded warrants financial
"to amend the evergreen provision to include any outstanding pre-funded warrants in the total number of shares of common stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
2020 Stock Option and Incentive Plan financial
"approved an amendment to the Company’s 2020 Stock Option and Incentive Plan to amend the evergreen provision"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did C4 Therapeutics (CCCC) stockholders decide at the June 24, 2026 annual meeting?
Stockholders elected three Class III directors, approved executive compensation on a non-binding basis, ratified KPMG LLP as auditor for 2026, and approved an amendment to the 2020 Stock Option and Incentive Plan affecting how the evergreen share increase is calculated.
Which directors were elected at C4 Therapeutics (CCCC) 2026 annual meeting and for how long?
Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors. Each will serve until the 2029 annual meeting of stockholders and until a successor is elected and qualified or earlier resignation or removal occurs under the company’s governance framework.
How did C4 Therapeutics (CCCC) stockholders vote on executive compensation in 2026?
Stockholders cast a non-binding, advisory vote approving named executive officer compensation, with 54,935,574 votes for, 1,070,926 against, and 38,870 abstentions. There were 21,049,125 broker non-votes. This advisory vote expresses stockholder views on pay but does not directly change compensation arrangements.
Which auditor did C4 Therapeutics (CCCC) stockholders ratify for the 2026 fiscal year?
Stockholders ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The ratification received 76,891,210 votes for, 185,427 against, and 17,858 abstentions, with no broker non-votes reported for this auditor ratification proposal.
What change was approved to C4 Therapeutics’ (CCCC) 2020 Stock Option and Incentive Plan?
Stockholders approved an amendment to the 2020 Stock Option and Incentive Plan to modify the evergreen provision so outstanding pre-funded warrants are included in the total shares outstanding each December 31 when calculating the annual evergreen increase, aligning plan capacity with this additional equity instrument.
Did any other matters come before C4 Therapeutics (CCCC) stockholders at the 2026 annual meeting?
No. The company reported that no other matters were submitted to, or voted on by, stockholders at the annual meeting beyond director elections, the advisory say-on-pay vote, auditor ratification, and the amendment to the 2020 Stock Option and Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates